Resistance management of Panitumumab

Panitumumab (Panitumumab) is a targeted drug used to treat certain malignant tumors. It is mainly used for KRAS mutation-negative colorectal cancer patients. However, as treatment progresses, some patients may develop drug resistance. In addition to KRAS mutations, there are other gene mutations that may lead to resistance to panitumumab, such as NRAS, BRAF, etc. By detecting the mutation status of these genes, it can be determined whether other resistance mechanisms exist and corresponding treatment strategies can be adopted.

The extrinsic mechanism of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer is that the plasticity of the tumor microenvironment confers resistance to EGFR-targeted therapy. Panitumumab inhibits tumors through ADCC mediated by NK cells and macrophages. By studying characteristics such as changes in signaling pathways and escape from apoptosis in drug-resistant cell lines or clinical samples, the causes of drug resistance can be revealed. Combining panitumumab with other targeted drugs or traditional chemotherapy drugs can increase the effectiveness of treatment and reduce the likelihood of resistance. For example, synergistic effects may occur when combined with chemotherapy drugs such as fluorouracil or oxaliplatin.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.